U.S. Markets close in 5 hrs 14 mins
  • S&P 500

    3,597.07
    -41.28 (-1.13%)
     
  • Dow 30

    29,491.87
    -418.50 (-1.40%)
     
  • Nasdaq

    12,036.74
    -169.10 (-1.39%)
     
  • Russell 2000

    1,829.49
    -25.78 (-1.39%)
     
  • Crude Oil

    45.10
    -0.43 (-0.94%)
     
  • Gold

    1,775.20
    -12.90 (-0.72%)
     
  • Silver

    22.39
    -0.25 (-1.10%)
     
  • EUR/USD

    1.1980
    +0.0010 (+0.0839%)
     
  • 10-Yr Bond

    0.8500
    +0.0080 (+0.95%)
     
  • Vix

    22.12
    +1.28 (+6.14%)
     
  • GBP/USD

    1.3329
    +0.0015 (+0.1093%)
     
  • USD/JPY

    104.2420
    +0.1570 (+0.1508%)
     
  • BTC-USD

    19,464.05
    +130.22 (+0.67%)
     
  • CMC Crypto 200

    380.64
    +16.04 (+4.40%)
     
  • FTSE 100

    6,342.77
    -24.81 (-0.39%)
     
  • Nikkei 225

    26,433.62
    -211.09 (-0.79%)
     

Timothy Springer of Selecta Biosciences, Inc. (NASDAQ:SELB) Just Spent US$9.6m On Shares

Simply Wall St
·3 min read

Those following along with Selecta Biosciences, Inc. (NASDAQ:SELB) will no doubt be intrigued by the recent purchase of shares by insider Timothy Springer, who spent a stonking US$9.6m on stock at an average price of US$2.62. Not only is that a big swing, but it increased their holding size by 20%, which is definitely great to see.

View our latest analysis for Selecta Biosciences

Selecta Biosciences Insider Transactions Over The Last Year

In fact, the recent purchase by Timothy Springer was the biggest purchase of Selecta Biosciences shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at around the current price of US$2.83. Of course they may have changed their mind. But this suggests they are optimistic. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Selecta Biosciences insiders decided to buy shares at close to current prices.

In the last twelve months Selecta Biosciences insiders were buying shares, but not selling. The average buy price was around US$2.21. It is certainly positive to see that insiders have invested their own money in the company. But we must note that the investments were made at well below today's share price. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership of Selecta Biosciences

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that Selecta Biosciences insiders own 22% of the company, worth about US$66m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Do The Selecta Biosciences Insider Transactions Indicate?

It is good to see recent purchasing. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Insiders likely see value in Selecta Biosciences shares, given these transactions (along with notable insider ownership of the company). So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To that end, you should learn about the 3 warning signs we've spotted with Selecta Biosciences (including 1 which is significant).

Of course Selecta Biosciences may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.